Lingling Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lingling Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hongyun Lu
Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University)
2 shared publications Zhanjin Lu
The Fifth Affiliated Hospital, Sun Yat-sen University
2 shared publicationsChang Li
Department of Cardiology Hubei No. 3 People's Hospital of Jianghan University Wuhan Hubei China
1 shared publicationJianfang Ye
Department of Endocrinology & Metabolism the Fifth Affiliated Hospital of Sun Yat‐sen University Zhuhai Guangdong China
1 shared publication- Jin Mei
Institute of Engineering Medicine, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Haishu District, Ningbo, 315010, China
1 shared publication Junlu Tong
Department of Endocrinology & Metabolism the Fifth Affiliated Hospital of Sun Yat‐sen University Zhuhai Guangdong China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 328 (1) , E92-E104
Hepatocyte HIF-2α aggravates NAFLD by inducing ferroptosis through increasing extracellular iron
The experiment demonstrated that HIF-2α increased extracellular iron. In LO2 cells overexpressing HIF-2α, FFAs not only increased cellular lipid and triglyceride levels but also induced key features of ferroptosis, such as reduced GSH and GPX4 levels and increased LPO, despite the absence of cellular iron overload. These effects were reversed by lowering extracellular iron with DFO. Furthermore, DFO treatment increased β-oxidation protein expression and improved lipid deposition in hepatocytes, potentially through the PI3K/AKT pathway.
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 328 (1) , E92-E104
Open AccessHepatocyte HIF-2α aggravates NAFLD by inducing ferroptosis through increasing extracellular iron
The experiment demonstrated that HIF-2α increased extracellular iron. In LO2 cells overexpressing HIF-2α, FFAs not only increased cellular lipid and triglyceride levels but also induced key features of ferroptosis, such as reduced GSH and GPX4 levels and increased LPO, despite the absence of cellular iron overload. These effects were reversed by lowering extracellular iron with DFO. Furthermore, DFO treatment increased β-oxidation protein expression and improved lipid deposition in hepatocytes, potentially through the PI3K/AKT pathway.
- Open Access
- 15 June 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (12) , e018451
Chronic Cardio‐Metabolic Disease Increases the Risk of Worse Outcomes Among Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, and Real‐World Study
Background: Although chronic cardio‐metabolic disease is a common comorbidity among patients with COVID‐19, its effects on the clinical characteristics and outcome are not well known. Methods and Results: This study aimed to explore the association between underlying cardio‐metabolic disease and mortality with COVID‐19 among hospitalized patients. This multicenter, retrospective, and real‐world study was conducted from January 22, 2020 to March 25, 2020 in China. Data between patients with and without 5 main cardio‐metabolic diseases including hypertension, diabetes mellitus, coronary heart disease, cerebrovascular disease, and hyperlipidemia were compared. A total of 1303 hospitalized patients were included in the final analysis. Of them, 520 patients (39.9%) had cardio‐metabolic disease. Compared with patients without cardio‐metabolic disease, more patients with cardio‐metabolic disease had COVID‐related complications including acute respiratory distress syndrome (9.81% versus 3.32%; P P= 0.001), secondary infection (13.9% versus 9.8%; P= 0.026), hypoproteinemia (12.1% versus 5.75%; P P P P= 0.021), and required mechanical ventilation (9.8% versus 4.3%; P 2, the mortality was 4.2%, 11.1%, and 19.8%, respectively. The multivariable‐adjusted hazard ratio of mortality among patients with cardio‐metabolic disease was 1.80 (95% CI, 1.17–2.77). Conclusions: Cardio‐metabolic disease was a common condition among hospitalized patients with COVID‐19, and it was associated with higher risks of in‐hospital mortality.
- 15 June 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (12) , e018451
Open AccessChronic Cardio‐Metabolic Disease Increases the Risk of Worse Outcomes Among Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, and Real‐World Study
Background: Although chronic cardio‐metabolic disease is a common comorbidity among patients with COVID‐19, its effects on the clinical characteristics and outcome are not well known. Methods and Results: This study aimed to explore the association between underlying cardio‐metabolic disease and mortality with COVID‐19 among hospitalized patients. This multicenter, retrospective, and real‐world study was conducted from January 22, 2020 to March 25, 2020 in China. Data between patients with and without 5 main cardio‐metabolic diseases including hypertension, diabetes mellitus, coronary heart disease, cerebrovascular disease, and hyperlipidemia were compared. A total of 1303 hospitalized patients were included in the final analysis. Of them, 520 patients (39.9%) had cardio‐metabolic disease. Compared with patients without cardio‐metabolic disease, more patients with cardio‐metabolic disease had COVID‐related complications including acute respiratory distress syndrome (9.81% versus 3.32%; P P= 0.001), secondary infection (13.9% versus 9.8%; P= 0.026), hypoproteinemia (12.1% versus 5.75%; P P P P= 0.021), and required mechanical ventilation (9.8% versus 4.3%; P 2, the mortality was 4.2%, 11.1%, and 19.8%, respectively. The multivariable‐adjusted hazard ratio of mortality among patients with cardio‐metabolic disease was 1.80 (95% CI, 1.17–2.77). Conclusions: Cardio‐metabolic disease was a common condition among hospitalized patients with COVID‐19, and it was associated with higher risks of in‐hospital mortality.